Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7841-7850 Newer>

The Motley Fool August 31, 2011 Seth Jayson	1 Reason Illumina May Be Headed for a Slowdown Illumina seems to be handling inventory well enough, but the individual segments don't provide a clear signal.
The Motley Fool August 31, 2011 Harsh Chauhan	Medtronic Looks Set for Takeoff Medtronic shares jump after flat quarterly growth as it looks toward global expansion.
The Motley Fool August 30, 2011 Brian Orelli	Aeterna Zentaris Passes Its Test AEZS-130, its diagnostic test for adult growth hormone deficiency, looks good.
The Motley Fool August 30, 2011 Brian Orelli	Pfizer and Bristol-Myers Glide Through For Pfizer and Bristol-Myers Squibb's new atrial fibrillation treatment, Eliquis, the devil seems to have left the building.
The Motley Fool August 30, 2011 Rex Moore	Let's See if Intuitive Surgical's Growth Is for Real Here are Intuitive Surgical's numbers, as well as a bonus look at a few other companies in its industry.
The Motley Fool August 29, 2011 Brian Orelli	We Can Make More! Too Bad Few Want It Dendreon is no longer constrained by its supply.
The Motley Fool August 29, 2011 Brian Orelli	Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.
The Motley Fool August 29, 2011 Seth Jayson	Here's How Omnicell Is Making You So Much, So Fast With both 12-month and quarterly CCC running better than average, Omnicell gets high marks in this cash-conversion checkup.
The Motley Fool August 29, 2011 Anders Bylund	Idenix Pharmaceuticals' Shares Popped: What You Need to Know Shares of viral-disease medication developer Idenix Pharmaceuticals climbed 10.9% on vanishingly thin trading volume.
The Motley Fool August 29, 2011 Brian Orelli	A Less Painful FDA Decision Johnson & Johnson gains approval of Nucynta ER.
<Older 7841-7850 Newer> Return to current articles.